Comparative Pharmacology
Head-to-head clinical analysis: AURLUMYN versus VYLOY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AURLUMYN versus VYLOY.
AURLUMYN vs VYLOY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
VYLOY (zolbetuximab-clzb) is a chimeric IgG1 monoclonal antibody that binds to claudin 18.2 (CLDN18.2), a tight junction protein expressed on the surface of gastric cancer cells. Binding induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to tumor cell death.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
VYLOY (zolbetuximab-clzb) is administered intravenously at a dose of 800 mg every 2 weeks following a loading dose of 1200 mg on day 1 of cycle 1.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (CrCl <30 mL/min).
Approximately 2.2 hours (terminal elimination half-life); clinical context: supports twice-weekly dosing schedule.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Primarily hepatobiliary excretion into feces; minimal renal elimination (<1% unchanged in urine).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent